Search Results for: 19

— First-in-Class Drug Candidate to Prevent C. difficile to Begin Phase 2 Testing in 1st Quarter 2015 — ROCKVILLE, Md., Feb. 10, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced positive topline safety and tolerability results […]

— CEO to Participate on “Trust Your Gut” – Therapeutic Opportunities from the Microbiome Panel — — Company Voted “Most Distinguished Public Company” as part of the Buzz of BIO Contest — ROCKVILLE, Md., Feb. 3, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with

ROCKVILLE, Md., Jan. 7, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced today that Jeffrey Riley, CEO, is scheduled to present at the Biotech Showcase™ 2015 Conference next week in San Francisco, as follows: Date: Tuesday, January

— On Schedule to Release Topline Data from Phase 1b Clinical Trial and to Start Phase 2 Clinical Trial of SYN-004 in 1Q 2015 — ROCKVILLE, Md., Dec. 30, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today

— First-in-Class Drug Candidate to Prevent C. difficile Ahead of Schedule for Phase 2 Testing to Begin in 1st Quarter 2015 — ROCKVILLE, Md., Dec. 22, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced positive topline

— First-in-Class Clinical Program Targets Protection of Microbiome to Prevent Overgrowth of Deadly C. difficile Infection Linked with Use of IV Antibiotics — ROCKVILLE, Md., Dec. 2, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that

— Phase 1a and 1b Trials to Use SYN-004 to Protect Microbiome; Intended to Prevent Overgrowth of Potentially Deadly C. difficile Bacteria — ROCKVILLE, Md., Nov. 24, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that

— Company Completes $18.9 Million Net Registered Direct Offering; Finalizes Plans for Start of Clinical Trials in C. difficile and C-IBS — — Conference Call Today, November 14, 2014, at 8:30 a.m. (EST); U.S. Participants Call (888) 347-5280 or Join Webcast at http://www.videonewswire.com/event.asp?id=100975 — ROCKVILLE, Md., Nov. 14, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT:

— First Allowed Patent Application Directly Related to SYN-004 in the U.S. — ROCKVILLE, Md., Oct. 22, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel pathogen-specific therapies for serious infections and diseases, announced today that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a composition

— Mark Pimentel, M.D., FRCP(C), of Cedars-Sinai Medical Center Serves as Chairman — ROCKVILLE, Md., Oct. 15, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologics and drugs targeting specific pathogens that cause serious infections and diseases, announced today the expansion of its Clinical Advisory Board (CAB) created to support